Applied Therapeutics (NASDAQ:APLT) Downgraded to “Neutral” Rating by Robert W. Baird

Robert W. Baird lowered shares of Applied Therapeutics (NASDAQ:APLT) from an outperform rating to a neutral rating in a research report released on Friday morning, MarketBeat Ratings reports.

Several other equities analysts also recently commented on the company. Leerink Partners reaffirmed a “market perform” rating and issued a $1.00 target price (down previously from $2.00) on shares of Applied Therapeutics in a research report on Wednesday, December 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Applied Therapeutics in a research note on Monday. Finally, Leerink Partnrs lowered Applied Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 3rd. Five analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $1.25.

Applied Therapeutics Price Performance

Shares of APLT opened at $0.12 on Friday. The company’s 50-day moving average is $0.74 and its 200-day moving average is $0.55. The firm has a market capitalization of $16.93 million, a PE ratio of -1.17 and a beta of 1.99. Applied Therapeutics has a fifty-two week low of $0.11 and a fifty-two week high of $1.50.

Applied Therapeutics (NASDAQ:APLT) last announced its earnings results on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02. The company had revenue of $1.00 million for the quarter, compared to the consensus estimate of $0.25 million. Analysts predict that Applied Therapeutics will post -0.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Applied Therapeutics

Several institutional investors have recently made changes to their positions in the stock. CreativeOne Wealth LLC grew its position in Applied Therapeutics by 132.2% during the first quarter. CreativeOne Wealth LLC now owns 50,413 shares of the company’s stock worth $25,000 after buying an additional 28,701 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Applied Therapeutics during the 3rd quarter valued at $31,000. HighTower Advisors LLC bought a new stake in shares of Applied Therapeutics during the 1st quarter valued at $59,000. Scientech Research LLC acquired a new stake in shares of Applied Therapeutics during the 3rd quarter worth $64,000. Finally, Birchview Capital LP bought a new position in shares of Applied Therapeutics in the second quarter worth $87,000. 98.31% of the stock is currently owned by institutional investors.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.